Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety and Effectiveness of RTP-026 for Patients with ST-Elevation Myocardial Infarction (STEMI)

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a heart condition known as ST-Elevation Myocardial Infarction (STEMI), which is a type of heart attack. The study will evaluate a treatment called RTP-026, which is given as a solution through an intravenous infusion. The purpose of the study is to assess the safety, tolerability, and effectiveness of RTP-026 in patients who have experienced a STEMI.

Participants in the study will receive either the RTP-026 treatment or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will take place over a period of time, with multiple doses being administered to evaluate how well the treatment works and how safe it is for the patients.

Throughout the study, various health checks will be conducted, including monitoring vital signs, performing ECGs (electrocardiograms), and taking blood samples to measure specific markers related to heart health. The study aims to gather information on how RTP-026 affects the heart and overall recovery after a STEMI, with the goal of improving treatment options for this serious condition.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Participation begins after providing informed consent. This is a necessary step before any study-specific procedures can start.

  2. Step 2

    Initial assessment

    Eligibility is confirmed based on criteria such as age, gender, and specific medical conditions related to ST-Elevation Myocardial Infarction (STEMI).

    An initial evaluation includes an electrocardiogram (ECG) to confirm STEMI and other tests to ensure eligibility for primary percutaneous coronary intervention (PCI).

  3. Step 3

    Treatment administration

    The treatment involves receiving RTP-026 or a placebo through an intravenous infusion. The specific dosage and frequency are determined by the study protocol.

    The primary goal is to assess the safety and effectiveness of RTP-026 compared to a placebo.

  4. Step 4

    Monitoring and follow-up

    Regular monitoring includes checking for any adverse events, changes in vital signs, and conducting ECGs and laboratory tests.

    Blood samples are taken at baseline, 6 hours, 12 hours, and 24 hours after PCI to measure specific markers like cTnT and CK-MB.

  5. Step 5

    Imaging and further assessments

    Cardiac magnetic resonance (CMR) imaging is performed within 48 hours and again 90 days after PCI to assess heart function and damage.

    Additional blood tests are conducted to measure changes in markers such as Pro-BNP, hsCRP, and NLR.

  6. Step 6

    Final evaluation

    The study concludes with a final assessment of the treatment's impact on heart function and overall health.

    The primary and secondary endpoints are evaluated, including safety, tolerability, and any major adverse cardiac events (MACE).

Who can join the trial?

6 criteria

  • The patient must give their permission to join the study before any study-related activities begin.
  • The patient must be a man between 18 and 80 years old or a woman who has stopped having menstrual periods for at least 12 months and is up to 80 years old.
  • The patient must have had sudden chest pain for less than 12 hours.
  • The patient must have a specific type of heart attack called **ST-Elevation Myocardial Infarction (STEMI)**, which is identified by certain patterns on an **ECG** (a test that checks the heart's electrical activity).
  • The patient must be eligible for a procedure called **primary PCI**, which is a treatment to open blocked heart arteries.
  • The patient must have a **NLR** (a type of blood test result) between 7 and 17 when they arrive at the hospital or right after the PCI procedure.

Who cannot join the trial?

3 criteria

  • Patients who have had a recent **ST-Elevation Myocardial Infarction (STEMI)**, which is a type of heart attack.
  • Individuals who are not within the specified age range for the study.
  • Participants who are part of a vulnerable population, meaning they might be at higher risk of harm or exploitation.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

RTP-026 is a medication being studied for its safety, tolerability, and effectiveness in patients who have experienced a type of heart attack known as ST-Elevation Myocardial Infarction (STEMI). The trial aims to understand how well RTP-026 works in helping patients recover from this condition and to ensure that it is safe for use.

What is already known about the treatment

RTP-026 – RTP-026 is administered orally and is currently being studied in clinical trials for its safety, tolerability, and efficacy in patients with ST-Elevation Myocardial Infarction (STEMI). It is not yet approved for general medical use, as it is still under investigation. The main therapeutic indication for RTP-026 is to assist in the treatment of STEMI, a severe type of heart attack. At the molecular level, RTP-026 is believed to work by modulating specific pathways involved in cardiac function, although the exact mechanism is still being researched. It falls under the pharmacological classification of cardiovascular agents.

Investigated diseases

ST-Elevation Myocardial Infarction (STEMI) – This is a type of heart attack characterized by a significant elevation in the ST segment on an electrocardiogram (ECG). It occurs when a coronary artery is completely blocked, preventing blood from reaching a part of the heart muscle. As a result, the affected heart tissue begins to die due to lack of oxygen. Symptoms often include chest pain, shortness of breath, and discomfort in other areas of the upper body. The progression of the disease can lead to complications such as heart failure or arrhythmias if not addressed promptly. Immediate medical intervention is crucial to restore blood flow and minimize heart damage.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-509182-21-00Estimated enrolment101 patientsSponsorResoTher Pharma A/S

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.